Anthera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ANTH 1.70 -0.05 (-2.86%)
price chart
PowerSecure International Inc. (POWR), Anthera Pharmaceuticals Inc (ANTH ...
Last Friday, Kevin Kotler's Broadfin Capital disclosed a marked increase (of almost 70%) in its exposure to Anthera Pharmaceuticals Inc (NASDAQ:ANTH). According to a Schedule 13G filed with the Securities and Exchange Commission, the fund now owns ...
Will Recent Contracts Bolster Investor Confidence In Anthera Pharmaceuticals ...
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) recently announced that it is considering various options for overseas development of blisibimod for both lupus and IgA nephropathy indications.
Commercial Developments At Anthera Pharmaceuticals Inc (NASDAQ:ANTH)
Dallas, Texas 12/16/2014 (FINANCIALSTRENDS) - Anthera Pharmaceuticals Inc (NASDAQ:ANTH) recently entered into an exclusive license agreement for its subcutaneous blisibimod with Tokyo-based Zenyaku Kogyo Co.
Related articles »  
4 Reasons To Buy Anthera Pharmaceuticals
Anthera Pharmaceutical has recently presented the results of the Phase IIb on their studies for the treatment of systemic lupus erythematosus.
Related articles »  
Anthera Pharmaceuticals, Inc. (ANTH) Posts Q1 Loss of 39c/Share
Additional information and publications from the CHABLIS-SC1 clinical study can be found at http://www.anthera.com/studies_chablis-sc1.
Anthera Pharmaceuticals Reports 2014 First Quarter Financial Results and ...  MarketWatch
Related articles »  
Anthera Pharmaceuticals Inc (ANTH): Anthera Pharmaceuticals: Recent ...
In our first report on Anthera Pharmaceuticals (NASDAQ:ANTH), we looked at Blisibimod's performance in the PEARL-SC trial, and how we should value the company from those results. We encourage people to read that report prior to this one.
Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and ...
HAYWARD, Calif., Nov. 14, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. ANTH, +4.06% today announced financial results and operational update for the third quarter ended September 30, 2014.
Related articles »  
Anthera Pharma (ANTH) Reports Exclusive License Agreement for Blisibimod in ...
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Anthera and Zenyaku Kogyo Co., Ltd. of Tokyo, Japan executed an exclusive license agreement for the development and commercialization of subcutaneous blisibimod in Japan and ...
Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Zenyaku ...  SYS-CON Media (press release)
Related articles »  
Anthera Pharmaceuticals, Inc. ( Nasdaq:ANTH) reports Q3 EPS (31c ...
Anthera Pharmaceuticals, Inc. ( Nasdaq:ANTH) reports Q3 EPS (31c), consensus (39c). Anthera Pharmaceuticals (ANTH) reported its Q3 results, with net loss for the three months ended September 30, 2014 at $7.0 million, compared to $5.8 million for the ...
Anthera Pharmaceuticals (ANTH) Releases Quarterly Earnings Results  Mideast Time
Anthera Pharmaceuticals (ANTH) Posts Quarterly Earnings Results, Beats ...  Ticker Report
Related articles »  
Anthera Pharmaceuticals Announces Update on Strategic Partnership ...
HAYWARD, Calif., Oct. 1, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
Related articles »